Nocturia
Conditions
Keywords
nocturia, bladder, urination disorders, hydrochlorothiazide, terazosin
Brief summary
The aim of the present study was to determine whether the combined administration of a diuretic agent, hydrochlorothiazide, at night would improve the frequency of nocturia unresponsive to alpha-blocker monotherapy in men with LUTS.
Detailed description
Because nocturia may result in sleep disturbances, daytime fatigue, a lower level of general well-being, and an increased risk of falling at night, it is among the most bothersome of the lower urinary tract symptoms (LUTS). Nocturia is related to a variety of conditions such as aging, overactive bladder (OAB), benign prostatic hyperplasia (BPH)/LUTS, medications, diabetes mellitus, diabetes insipidus, anorexia nervosa, and sleep disturbance. In a previous study, we suggested that treatment with terazosin can reduce episodes of nocturia, both subjectively and objectively, in some men with LUTS. Other study showed that in men with nocturnal polyuria, furosemide resulted in a significant reduction in night-time frequency and percentage of the voided volume.
Interventions
DRUGcombination therapy of terazosin and hydrochlorothiazide
25 mg of hydrochlorothiazide eight hours before bedtime and 4 mg of terazosin at bedtime for 4 weeks
Sponsors
Seoul National University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Healthy volunteers
No
Inclusion criteria
* no response or \< 25% reduction in subjective nocturia by the IPSS question 7 after 4-weeks of treatment with terazosin * no response or \< 25% reduction in objective nocturia by the FVC after 4-weeks of treatment with terazosin * nocturia on average two times or more per night (according to the FVC) after 4-weeks of terazosin therapy
Exclusion criteria
* use of medications for the control of bladder symptoms * use of sedatives or tranquillisers for treating sleep disturbances * bladder tumours * bladder stones * urethral strictures * neurogenic bladder dysfunction * restricted mobility * working primarily at night * a documented history or clinical symptoms of prostatitis, prostate cancer, or prostatic intraepithelial neoplasia on biopsy * serum PSA levels of \>20 ng/mL * a history of prostate surgery or radiotherapy, acute urinary retention or an indwelling catheter * evidence of acute urinary infection (pyuria and bacteriuria)on urine analysis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-day frequency-volume chart | at baseline and at the end of the 4-week therapy |
Secondary
| Measure | Time frame |
|---|---|
| International Prostate Symptom Score (IPSS) question 7 | at baseline and at the end of the 4-week therapy |
Countries
South Korea
Outcome results
None listed